Literature DB >> 22171991

Identification of antigenic variants of the porcine rubulavirus in sera of field swine and their seroprevalence.

A C Escobar-López1, J F Rivera-Benitez, H Castillo-Juárez, H Ramírez-Mendoza, M E Trujillo-Ortega, J I Sánchez-Betancourt.   

Abstract

We sampled sera from 1013 non-vaccinated swine from four states in Mexico, Guanajuato, Jalisco, Michoacán and the Estado de Mexico, to analyse anti-porcine rubulavirus antibody titres against three different porcine rubulavirus isolates (PAC-4/1993, PAC-6/2001, and PAC-9/2003) using a hemagglutination inhibition assay. The results revealed that there were antigenic differences among the isolates assessed. In particular, the estimated correlation between the PAC-4/1993 and PAC-6/2001 (0.50) isolates and between the PAC-4/1993 and PAC-9/2003 isolates (0.56) displayed a moderate positive correlation. In contrast, there was a strong positive correlation between the PAC-6/2001 and PAC-9/2003 isolates (0.73). We also found that in the state of Guanajuato, PAC-4/1993 was the isolate that was most frequently identified; in Jalisco, the isolate was PAC-6/2001; and in Michoacán, the isolate was PAC-9/2003. By contrast, in the Estado de Mexico, all three isolates appeared to circulate with a low seroprevalence. In general, the analysed sera from the four states displayed a porcine rubulavirus serological prevalence ranging from 9% to 23.7%. These data indicate that there is not complete antibody cross-antigenicity among the three isolates, and the antigenic variations in the antibody response found in this study implies that the use of a monovalent vaccine would not generate complete protection against the different antigenic subtypes.
© 2011 Blackwell Verlag GmbH.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22171991     DOI: 10.1111/j.1865-1682.2011.01286.x

Source DB:  PubMed          Journal:  Transbound Emerg Dis        ISSN: 1865-1674            Impact factor:   5.005


  6 in total

1.  Molecular characterisation of Porcine rubulavirus (PorPV) isolates from different outbreaks in Mexico.

Authors:  S Cuevas-Romero; J F Rivera-Benítez; A-L Blomström; M Ramliden; E Hernández-Baumgarten; P Hernández-Jáuregui; H Ramírez-Mendoza; M Berg
Journal:  Virus Genes       Date:  2016-01-04       Impact factor: 2.332

2.  La Piedad Michoacán Mexico Virus V protein antagonizes type I interferon response by binding STAT2 protein and preventing STATs nuclear translocation.

Authors:  Giuseppe Pisanelli; Maudry Laurent-Rolle; Balaji Manicassamy; Alan Belicha-Villanueva; Juliet Morrison; Bernardo Lozano-Dubernard; Felipa Castro-Peralta; Giuseppe Iovane; Adolfo García-Sastre
Journal:  Virus Res       Date:  2015-11-03       Impact factor: 3.303

3.  Co-infection of classic swine H1N1 influenza virus in pigs persistently infected with porcine rubulavirus.

Authors:  José Francisco Rivera-Benitez; Jazmín De la Luz-Armendáriz; Manuel Saavedra-Montañez; Miguel Ángel Jasso-Escutia; Ivan Sánchez-Betancourt; Armando Pérez-Torres; Julio Reyes-Leyva; Jesús Hernández; Atalo Martínez-Lara; Humberto Ramírez-Mendoza
Journal:  Vet Microbiol       Date:  2016-01-07       Impact factor: 3.293

4.  Development of Novel Recombinant Antigens of Nucleoprotein and Matrix Proteins of Porcine orthorubulavirus: Antigenicity and Structural Prediction.

Authors:  Rocío Lara-Romero; José Luis Cerriteño-Sánchez; Susana Mendoza-Elvira; José Bryan García-Cambrón; María Azucena Castañeda-Montes; José Manuel Pérez-Aguilar; Julieta Sandra Cuevas-Romero
Journal:  Viruses       Date:  2022-09-01       Impact factor: 5.818

5.  Molecular and epidemiological studies of Porcine rubulavirus infection - an overview.

Authors:  Julieta Sandra Cuevas-Romero; Anne-Lie Blomström; Mikael Berg
Journal:  Infect Ecol Epidemiol       Date:  2015-11-18

6.  Development of a real-time RT-PCR method for detection of porcine rubulavirus (PoRV-LPMV).

Authors:  Sandra Cuevas-Romero; Anne-Lie Blomström; Arcelia Alvarado; Pablo Hernández-Jauregui; Francisco Rivera-Benitez; Humberto Ramírez-Mendoza; Mikael Berg
Journal:  J Virol Methods       Date:  2013-01-07       Impact factor: 2.014

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.